Posted on 1/18/18
What's Juno Therapeutics Worth to Celgene?
Celgene Corp. (NASDAQ:CELG) owns ex-U.S. rights to Juno Therapeutics' (NASDAQ:JUNO)lead drug, liso-cel (formerly JCAR017), and it owns nearly 10% of Juno Therapeutics' stock, yet that may . . .
Posted on 1/17/18
Johnson & Johnson Issues Statement on ZYTIGA Inter Partes Reviews
Johnson & Johnson (NYSE: JNJ) issued the following statement regarding today's Inter Partes Reviews regarding ZYTIGA® (abiraterone acetate):"We are disappointed in and strongly disagree with the . . .
Posted on 1/17/18
Vantage Cancer Care Network Collaborates With Alliance Cancer Specialists
PHILADELPHIA--(BUSINESS WIRE)--Vantage Cancer Care Network (VCCN), a leader in value-based integrated cancer care, announced an agreement with Alliance Cancer Specialists, PC, to expand the delivery of . . .
Posted on 1/17/18
Cerveau Technologies Signs Research Agreement with University of Pittsburgh
BOSTON--(BUSINESS WIRE)--Cerveau Technologies Inc. today announced an agreement with the University of Pittsburgh to support multiple projects over the next several years. These research projects are . . .
Posted on 1/16/18
5 Biotech Stocks That Could Be Bought Out in 2018
Biotechnology merger and acquisition activity could get a booster shot now that U.S. tax reform is cutting corporate tax rates and allowing companies to repatriate cash . . .
Posted on 1/12/18
Here's What Celgene's Management Just Said About Its Future
Celgene Corp. (NASDAQ:CELG) has been one of biotech's brightest stars over the past decade, but its shares lost some luster following third-quarter 2017 financial results that . . .
Posted on 1/12/18
The Laundry List of Reasons Behind Teva Pharmaceutical Industries' 48% Tumble in 2017
What happenedShares of Teva Pharmaceutical Industries (NYSE:TEVA), the world's leading generic drug developer and a producer of brand-name medicines, crashed by 48% in 2017, according to . . .
Posted on 1/11/18
Teva: This Is Simply Too Great To Miss
Investment ThesisTeva (TEVA) offers long-term patient investors a strong opportunity to participate in its growth potential without the hefty price tag. The reason being that two . . .
Posted on 1/11/18
Celgene Tries To Rejoin The Party
BackgroundCelgene (CELG) has rejoined the group of biotechs trading at the same price they first reached when ascending to new heights in 2014. At $105-106 as . . .
Posted on 1/11/18
Celgene: Parsing Through The $7 Billion Impact Acquisition
Celgene CEO Mark AllesPresident Trump's tax cuts were expected to usher in a round of share buybacks and acquisitions in the biotechnology space. Celgene (CELG) answered . . .
Posted on 1/11/18
Better Stock: AbbVie Inc (ABBV) vs. Johnson & Johnson (JNJ)
The last five years have been kind to nearly all investors. But health-focused companies like Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) have been particularly profitable . . .
Posted on 1/10/18
Braeburn Announces Completion of $110 Million Financing
Braeburn Pharmaceuticals, Inc. (Braeburn) today announced that the Company has completed a $110 million mezzanine round of financing led by Wellington Capital Management. Other new investors . . .
Posted on 1/10/18
Celgene - Strong Portfolio Should Support Growing Earnings
Celgene (NASDAQ: CELG) is a more than $80 billion biotech company that hurt its investors in late October, after a difficult environment forced the company to . . .
Posted on 1/10/18
The 1 Word That Explains Why Pfizer's Future Looks Brighter Than Its Past
Pfizer's (NYSE:PFE) president of worldwide research and development, Mikael Dolsten, represented the giant drugmaker at the annual J. P. Morgan (NYSE:JPM) Healthcare Conference on Monday. Dolsten's . . .
Posted on 1/10/18
Johnson & Johnson Wants to Create a Crisis -- and That's Great for Investors
Johnson & Johnson (NYSE:JNJ) CEO Alex Gorsky, along with CFO Dominic Caruso, sat down on Monday to answer questions at the annual J.P. Morgan Healthcare Conference. . . .
Posted on 1/10/18
3 Dividend Stocks That Cut Bigger Checks Than Johnson & Johnson
Healthcare giant Johnson & Johnson (NYSE:JNJ) pays a nice dividend. Based on its latest quarterly payout, the stock yields about 2.3%. That may not seem all . . .
Posted on 1/9/18
Banner Health And Select Medical Enter Joint Venture
Select Medical today announced a joint venture agreement with Banner Health to combine operations of more than 38 physical therapy centers in Arizona and four acute . . .
Posted on 1/9/18
Pfizer (PFE) Presents at JPMorgan Healthcare Conference - Transcript
Pfizer Inc. (NYSE:PFE) JPMorgan Healthcare Conference January 8, 2018 11:30 AM ETExecutivesMikael Dolsten - President, Worldwide Research and DevelopmentAnalystsChris Schott - J.P. MorganChris SchottGood morning, everybody. . . .
Posted on 1/9/18
Johnson & Johnson: A Good Value In This Overheated Market
Johnson & Johnson is a blue chip dividend aristocratWhen I think of Johnson & Johnson (JNJ), I can’t help but think of high quality. Many refer . . .
Posted on 1/9/18
Johnson & Johnson (JNJ) Management Presents at 36th Annual JPMorgan Healthcare Conference 2018 - Brokers Conference Transcript
Johnson & Johnson (NYSE:JNJ) Company Conference Presentation January 8, 2018 5:30 PM ETExecutivesAlex Gorsky - Chairman and Chief Executive OfficerDominic Caruso - EVP and Chief Financial . . .
Posted on 1/9/18
Celgene (CELG) CEO Mark Alles Presents at 36th Annual JPMorgan Healthcare Brokers Conference - Slides
The following slide deck was published by Celgene Corporation in conjunction with this event. 136READ FULL ARTICLE HERE
Posted on 1/9/18
Celgene: Impact Biomedicines To Broaden The Pipeline
Celgene (CELG) has joined the M&A craze at the start of 2018 with the purchase of privately-held Impact Biomedicines. The deal is structured in a savvy . . .
Posted on 1/8/18
3 Big Biotech Stocks to Buy in January
Biotech was hot yet again in 2017. The SPDR S&P Biotech ETF soared more than 43% last year. Many biotech stocks performed even better than that.For . . .
Posted on 1/8/18
Idera Pharmaceuticals Provides 2018 Update and Outlook
EXTON, Pa. and CAMBRIDGE, Mass., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization . . .
Posted on 1/8/18
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that onJanuary 3, 2018 it approved non-statutory stock options to purchase an aggregate of 33,200 shares of its common . . .

